Multiple Myeloma Patient Registry
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Multiple Myeloma Patient Registry

Sponsor: Janssen Scientific Affairs, LLC

The purpose of this study is to document the participants characteristics, disease burden, and clinical management of participants in the United States who are treated for relapsed multiple myeloma in routine medical practice with a treatment strategies that include a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) used either as monotherapy or combination therapy with other treatments. This study involves the completion of paper surveys.